Cytokinetics Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Cytokinetics Inc trades at $77.1 (market cap $10.63B), while Vanguard Total Stock Market Index Fund ETF trades at $381.8. The key difference: Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | VTI | |
|---|---|---|
Market Cap | $10.63B | — |
Sector | Technology | — |
52-Week High | $87.26 | $381.78 |
52-Week Low | $34.31 | $311.68 |
Enterprise Value | $10.74B | — |
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
VTI trades at $381.85, up 0.06% with a bullish technical signal from moving averages. The ETF maintains broad diversification across 3,500+ US stocks with a low 0.03% expense ratio. Recent institutional activity shows mixed positioning with some firms increasing holdings while others reduced exposure.
The outlook remains positive given VTI's role as a core total market holding, though the elevated RSI suggests potential near-term consolidation. Key risks include market concentration in large-cap tech and broader economic volatility affecting overall equity performance.
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →